MARKET

MDXG

MDXG

MIMEDX GROUP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.25
-0.01
-0.16%
After Hours: 6.20 -0.05 -0.80% 18:00 09/24 EDT
OPEN
6.20
PREV CLOSE
6.26
HIGH
6.44
LOW
6.13
VOLUME
1.11M
TURNOVER
--
52 WEEK HIGH
15.99
52 WEEK LOW
5.30
MARKET CAP
699.67M
P/E (TTM)
-8.1646
1D
5D
1M
3M
1Y
5Y
MDXG: Unexpected Results Call for a Revision
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT
Benzinga · 9h ago
BELLUS Health, aTyr Pharma leads healthcare gainers; Virpax Pharmaceuticals, RedHill Biopharma among major losers
Gainers: BELLUS Health (NASDAQ:BLU) +26%, aTyr Pharma (NASDAQ:LIFE) +22%, Jounce Therapeutics (NASDAQ:JNCE) +14%, NanoViricides (NYSE:NNVC) +12%, Matinas BioPharma (NYSE:MTNB) +12%. Losers: Virpax Pharmaceuticals (NASDAQ:VRPX) -37%, RedHill Biopharma (NASD...
Seekingalpha · 09/14 15:03
HC Wainwright Adjusts Price Target for MiMedx Group to $8.50 From $20, Maintains Buy Rating
MT Newswires · 09/14 10:31
HC Wainwright & Co. Maintains Buy on MiMedx Group, Lowers Price Target to $8.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MiMedx Group (NASDAQ:MDXG) with a Buy and lowers the price target from $20 to $8.5.
Benzinga · 09/14 10:13
72 Biggest Movers From Yesterday
Gainers
Benzinga · 09/14 08:50
Hot Stocks: Box office excitement; ITMR, TROX rise on M&A; MDXG failed trials; CVGW continues slide
While COVID remains one of the key risks facing the broader markets, there have been signs that the post-pandemic reopening has persisted even in the face of the Delta variant.
Seekingalpha · 09/13 21:44
Mid-Afternoon Market Update: Dow Rises Over 100 Points; Itamar Medical Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.38% to 34,739.18 while the NASDAQ fell 0.27% to 15,074.10. The S&P also fell, dropping 0.07% to 4,455.53.
Benzinga · 09/13 18:40
Mid-Day Market Update: Crude Oil Up 1%; MiMedx Group Shares Plummet
Midway through trading Monday, the Dow traded up 0.80% to 34,885.46 while the NASDAQ fell 0.10% to 15,100.02. The S&P also rose, gaining 0.23% to 4,468.75.
Benzinga · 09/13 16:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDXG. Analyze the recent business situations of MIMEDX GROUP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDXG stock price target is 13.83 with a high estimate of 23.00 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 159
Institutional Holdings: 61.48M
% Owned: 54.92%
Shares Outstanding: 111.95M
TypeInstitutionsShares
Increased
28
12.03M
New
45
2.92M
Decreased
26
2.36M
Sold Out
20
3.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
M. Kathleen Behrens Wilsey
Chief Executive Officer/Director
Timothy Wright
Chief Financial Officer/Executive Vice President - Finance
Peter Carlson
Executive Vice President
Rohit Kashyap
Executive Vice President
Robert Stein
Senior Vice President/Chief Compliance Officer
Mark Graves
Senior Vice President/Director of Investor Relations
Jack Howarth
Senior Vice President
Scott Turner
General Counsel/Secretary
William Hulse
Director
Phyllis Gardner
Independent Director
James Bierman
Independent Director
Michael Giuliani
Independent Director
William Hawkins
Independent Director
Cato Laurencin
Independent Director
K. Todd Newton
Independent Director
Martin Sutter
No Data
About MDXG
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Webull offers kinds of MiMedx Group Inc stock information, including NASDAQ:MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.